Aspects of epidemiology, pathology, virology, immunology, transmission, prevention, prognosis, diagnosis, and treatment of COVID-19 Pandemic: A narrative review

Pordanjani, Sajjad Rahimi; Hasanpour, A; Askarpour, Hasan; Bastam, Dariush; Rafiee, Mohammad; Khazaei, Zaher; Mazaheri, Elaheh; Vaziri, Mohammad Hossein; Sabour, Siamak

doi:10.4103/ijpvm.ijpvm_469_20

Cited by 9 publications

(1 citation statement)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to a bias determined by the pandemic environment, as viral pneumonia is a landmark of COVID-19. 15 This observation could also be a result of a reporting bias in cases where the initial diagnosis of viral pneumonia in association with a suspected COVID-19 infection was established, but not revised promptly after ruling out SARS-CoV-2 by means of polymerase chain reaction testing. 16 One previous investigation reports that the number of consultations in gastroenterological practices and corresponding diagnoses related to gastroenterological illness decreased gradually during the COVID-19 pandemic.…”

Section: Discussionmentioning

confidence: 99%

Fewer non‐COVID‐19 respiratory tract infections and gastrointestinal infections during the COVID‐19 pandemic

Tanislav

Kostev²

2021

Journal of Medical Virology

View full text Add to dashboard Cite

For preventing the spread of the coronavirus disease 2019 (COVID-19) pandemic, measures like wearing masks, social distancing, and hand hygiene played crucial roles. These measures may also have affected the expansion of other infectious diseases like respiratory tract infections (RTI) and gastro-intestinal infections (GII).Therefore, we aimed to investigate non-COVID-19 related RTI and GII during the COVID-19 pandemic. Patients with a diagnosis of an acute RTI (different locations) or acute GII documented anonymously in 994 general practitioner (GP) or 192 pediatrician practices in Germany were included. We compared the prevalence of

show abstract

Section: Discussionmentioning

confidence: 99%

Fewer non‐COVID‐19 respiratory tract infections and gastrointestinal infections during the COVID‐19 pandemic

Tanislav

Kostev²

2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions

Abulsoud¹,

El-Husseiny²,

El-Husseiny³

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study

Norton,

Thakur,

Ganguly

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectivePregnant women with COVID-19 are at elevated risk for severe outcomes, but clinical data on management of these patients are limited. Monoclonal antibodies, such as casirivimab plus imdevimab (CAS+IMD), have proven effective in treating non-pregnant adults with COVID-19, prompting further evaluation in pregnant women.MethodsA phase 3 portion of an adaptive, multicentre, randomised, double-blind, placebo-controlled trial evaluated the safety, clinical outcomes, pharmacokinetics and immunogenicity of CAS+IMD (1200 mg or 2400 mg) in the treatment of pregnant outpatients with COVID-19 (NCT04425629). Participants were enrolled between December 2020 and November 2021, prior to the emergence of Omicron-lineage variants against which CAS+IMD is not active. Safety was evaluated in randomised participants who received study drug (n=80); clinical outcomes were evaluated in all randomised participants (n=82). Only two pregnant participants received placebo, limiting conclusions regarding treatment effect. Infants born to pregnant participants were followed for developmental outcomes ≤1 year of age.ResultsIn pregnant participants, CAS+IMD was well tolerated, with no grade ≥2 hypersensitivity or infusion-related reactions reported. There were no participant deaths, and only one COVID-19–related medically attended visit. Although two pregnancies (3%) reported issues in the fetus/neonate, they were confounded by maternal history or considered to be due to an alternate aetiology. No adverse developmental outcomes in infants ≤1 year of age were considered related to in utero exposure to the study drug. CAS+IMD 1200 mg and 2400 mg rapidly and similarly reduced viral loads, with a dose-proportional increase in concentrations of CAS+IMD in serum. Pharmacokinetics were consistent with that reported in the general population. Immunogenicity incidence was low.ConclusionCAS+IMD treatment of pregnant outpatients with COVID-19 showed similar safety, clinical outcomes and pharmacokinetic profiles to that observed in non-pregnant adults. There was no evidence of an impact on developmental outcomes in infants ≤1 year of age.Trial registration numberNCT04425629.

show abstract

Aspects of epidemiology, pathology, virology, immunology, transmission, prevention, prognosis, diagnosis, and treatment of COVID-19 Pandemic: A narrative review

Cited by 9 publications

References 79 publications

Fewer non‐COVID‐19 respiratory tract infections and gastrointestinal infections during the COVID‐19 pandemic

Fewer non‐COVID‐19 respiratory tract infections and gastrointestinal infections during the COVID‐19 pandemic

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions

Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study

Contact Info

Product

Resources

About